title: [The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].
abstract: BACKGROUND
  The influence of antipsychotic medication on brain alterations in proton magnetic resonance spectroscopy (1H MRS) in schizophrenia can be the explanation of many discrepancies observed in the previous papers.
  
  
  OBJECTIVE
  The aim of this study was the evaluation of antipsychotic medication effect on the metabolite levels in the brain of schizophrenic patients based on 1H MRS examination.
  
  
  METHODS
  The group of 32 patients with a diagnosis of schizophrenia according to DSM-IV and 26 healthy controls were included into the study. The patients were examined twice--once after the period of at least 7 days without neuroleptics (baseline) and for the second time at least 4 weeks after stable doses ofneuroleptics (follow-up). 21 patients were receiving risperidone and 11--olanzapine. Proton resonance spectroscopy was performed on a 1.5 MR scanner. Each volume element (voxel) was localised in the left frontal lobe, in the left temporal lobe and in the left thalamus. Metabolite ratios: N-acetylaspartate (NAA) to creatine (Cr) and unsupressed water signal were analysed. Results. We found the significant increase of the NAA/Cr level in the thalamus in the group of patients treated with risperidone, we didn't observe similar changes in the olanzapine group.
  
  
  CONCLUSIONS
  Our results confirm that the neuroleptic drugs, especially atypicals, modify brain metabolism measured by 1H MRS. The pattern of the changes suggest a possible neuroprotective influence of the antipsychototic treatment in schizophrenic patients. The small group of the olanzapine treated patients doses not allow to make any conclusions regarding this type of medication.
authors.affiliation: Klinika Psychiatrii UM w Białymstoku.
authors.forename: Agata
authors.initials: A
authors.lastname: Szulc
authors.forename: Beata
authors.initials: B
authors.lastname: Galińiska
authors.forename: Eugeniusz
authors.initials: E
authors.lastname: Tarasów
authors.forename: Wojciech
authors.initials: W
authors.lastname: Dzienis
authors.forename: Bozena
authors.initials: B
authors.lastname: Kubas
authors.forename: Beata
authors.initials: B
authors.lastname: Konarzewska
authors.forename: Napoleon
authors.initials: N
authors.lastname: Waszkiewicz
authors.forename: Regina
authors.initials: R
authors.lastname: Popławska
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D000077152:Olanzapine; D012016:Reference Values; D018967:Risperidone / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D013702:Temporal Lobe / Q000187:drug effects; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine